Aspergillus: Rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999

P. H. Chandrasekar, J. L. Cutright, E. K. Manavathu

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We investigated the frequency of clinical isolation and the in vitro susceptibility to antifungal agents of Aspergillus species obtained from patients at the Detroit Medical Center from January 1994 to December 1999. During this period, 593 clinical isolates of Aspergillus species [406 A. fumigatus, 68%; 82 A. niger, 14%; 42 A. flavus, 7%; 63 Aspergillus spp., 11%] were recovered from hospitalized patients. From January 1996 to December 1999, approximately 2.5-4.5 fold yearly increase of the number of aspergillus isolates occurred compared to that of 1994. Conidial suspensions from clinical isolates were prepared and their in vitro susceptibility to amphotericin B and three azoles were determined. All four agents examined were extremely active. The minimum inhibitory concentrations (MIC90) (μg/mL) of amphotericin B, itraconazole, voriconazole and posaconazole for A. fumigatus (n = 406) were 0.5, 1.0, 0.5 and 0.25. Similar values were noted for non-A. fumigatus isolates. A year-to-year comparison of the MIC90 of the four agents for A. fumigatus and non-A. fumigatus isolates over the 6-year study period showed no significant differences. Our study showed a steady increase in the frequency of clinical isolation of Aspergillus species; and the organism has remained susceptible to amphotericin B/triazoles without any change in susceptibility levels during the 6-year study period.

Original languageEnglish (US)
Pages (from-to)211-214
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Volume41
Issue number4
DOIs
StatePublished - Dec 1 2001

Fingerprint

Antifungal Agents
Aspergillus
Amphotericin B
Azoles
Triazoles
Itraconazole
Microbial Sensitivity Tests
Suspensions
In Vitro Techniques

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Aspergillus : Rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999. / Chandrasekar, P. H.; Cutright, J. L.; Manavathu, E. K.

In: Diagnostic Microbiology and Infectious Disease, Vol. 41, No. 4, 01.12.2001, p. 211-214.

Research output: Contribution to journalArticle

@article{4bea2f9701084b49aba2c0f21cf38ca0,
title = "Aspergillus: Rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999",
abstract = "We investigated the frequency of clinical isolation and the in vitro susceptibility to antifungal agents of Aspergillus species obtained from patients at the Detroit Medical Center from January 1994 to December 1999. During this period, 593 clinical isolates of Aspergillus species [406 A. fumigatus, 68{\%}; 82 A. niger, 14{\%}; 42 A. flavus, 7{\%}; 63 Aspergillus spp., 11{\%}] were recovered from hospitalized patients. From January 1996 to December 1999, approximately 2.5-4.5 fold yearly increase of the number of aspergillus isolates occurred compared to that of 1994. Conidial suspensions from clinical isolates were prepared and their in vitro susceptibility to amphotericin B and three azoles were determined. All four agents examined were extremely active. The minimum inhibitory concentrations (MIC90) (μg/mL) of amphotericin B, itraconazole, voriconazole and posaconazole for A. fumigatus (n = 406) were 0.5, 1.0, 0.5 and 0.25. Similar values were noted for non-A. fumigatus isolates. A year-to-year comparison of the MIC90 of the four agents for A. fumigatus and non-A. fumigatus isolates over the 6-year study period showed no significant differences. Our study showed a steady increase in the frequency of clinical isolation of Aspergillus species; and the organism has remained susceptible to amphotericin B/triazoles without any change in susceptibility levels during the 6-year study period.",
author = "Chandrasekar, {P. H.} and Cutright, {J. L.} and Manavathu, {E. K.}",
year = "2001",
month = "12",
day = "1",
doi = "10.1016/S0732-8893(01)00295-4",
language = "English (US)",
volume = "41",
pages = "211--214",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Aspergillus

T2 - Rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999

AU - Chandrasekar, P. H.

AU - Cutright, J. L.

AU - Manavathu, E. K.

PY - 2001/12/1

Y1 - 2001/12/1

N2 - We investigated the frequency of clinical isolation and the in vitro susceptibility to antifungal agents of Aspergillus species obtained from patients at the Detroit Medical Center from January 1994 to December 1999. During this period, 593 clinical isolates of Aspergillus species [406 A. fumigatus, 68%; 82 A. niger, 14%; 42 A. flavus, 7%; 63 Aspergillus spp., 11%] were recovered from hospitalized patients. From January 1996 to December 1999, approximately 2.5-4.5 fold yearly increase of the number of aspergillus isolates occurred compared to that of 1994. Conidial suspensions from clinical isolates were prepared and their in vitro susceptibility to amphotericin B and three azoles were determined. All four agents examined were extremely active. The minimum inhibitory concentrations (MIC90) (μg/mL) of amphotericin B, itraconazole, voriconazole and posaconazole for A. fumigatus (n = 406) were 0.5, 1.0, 0.5 and 0.25. Similar values were noted for non-A. fumigatus isolates. A year-to-year comparison of the MIC90 of the four agents for A. fumigatus and non-A. fumigatus isolates over the 6-year study period showed no significant differences. Our study showed a steady increase in the frequency of clinical isolation of Aspergillus species; and the organism has remained susceptible to amphotericin B/triazoles without any change in susceptibility levels during the 6-year study period.

AB - We investigated the frequency of clinical isolation and the in vitro susceptibility to antifungal agents of Aspergillus species obtained from patients at the Detroit Medical Center from January 1994 to December 1999. During this period, 593 clinical isolates of Aspergillus species [406 A. fumigatus, 68%; 82 A. niger, 14%; 42 A. flavus, 7%; 63 Aspergillus spp., 11%] were recovered from hospitalized patients. From January 1996 to December 1999, approximately 2.5-4.5 fold yearly increase of the number of aspergillus isolates occurred compared to that of 1994. Conidial suspensions from clinical isolates were prepared and their in vitro susceptibility to amphotericin B and three azoles were determined. All four agents examined were extremely active. The minimum inhibitory concentrations (MIC90) (μg/mL) of amphotericin B, itraconazole, voriconazole and posaconazole for A. fumigatus (n = 406) were 0.5, 1.0, 0.5 and 0.25. Similar values were noted for non-A. fumigatus isolates. A year-to-year comparison of the MIC90 of the four agents for A. fumigatus and non-A. fumigatus isolates over the 6-year study period showed no significant differences. Our study showed a steady increase in the frequency of clinical isolation of Aspergillus species; and the organism has remained susceptible to amphotericin B/triazoles without any change in susceptibility levels during the 6-year study period.

UR - http://www.scopus.com/inward/record.url?scp=0035685502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035685502&partnerID=8YFLogxK

U2 - 10.1016/S0732-8893(01)00295-4

DO - 10.1016/S0732-8893(01)00295-4

M3 - Article

C2 - 11777662

AN - SCOPUS:0035685502

VL - 41

SP - 211

EP - 214

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 4

ER -